Treatment Responder Rates of Oral Atogepant for the Preventive Treatment of Chronic Migraine: Results From the PROGRESS Trial

被引：0

作者：

Lipton, Richard B. ^{[1
]}

Ashina, Messoud ^{[2
]}

Tassorelli, Cristina ^{[3
]}

Martin, Vincent ^{[4
]}

Yu, Sung Y. ^{[5
]}

Nagy, Krisztian ^{[6
]}

Schwefel, Brittany ^{[7
]}

Trugman, Joel ^{[5
]}

机构：

[1] Albert Einstein Coll Med, Bronx, NY USA

[2] Univ Copenhagen, Dept Neurol, Danish Headache Ctr, Rigshospitalet Glostrup, Cophenhagen, Denmark

[3] C Mondino Fdn & Univ Pavia, Headache Sci Ctr, Pavia, Italy

[4] Univ Cincinnati, Cincinnati, OH USA

[5] AbbVie, Madison, NJ USA

[6] AbbVie, Budapest, Hungary

[7] AbbVie, N Chicago, IL USA

来源：

CEPHALALGIA | 2022年 / 42卷 / 1_SUPPL期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

MTIS22-EP-

引用

页码：31 / 32

页数：2

共 50 条

[21] Atogepant vs. rimegepant cost per treatment responder analysis for the preventive treatment of episodic migraine
Ailani, J.
Gandhi, P.
Lalla, A.
Singh, R. B. Halker
McAllister, P.
Smith, J. H.
Dabruzzo, B.
Chalermpalanupap, N.
Nahas, S. J.
JOURNAL OF HEADACHE AND PAIN, 2024, 25
[22] Efficacy of Oral Atogepant in People With Chronic Migraine With and Without Acute Medication Overuse: Results From the PROGRESS Trial
Goadsby, P.
Friedman, D.
Holle-Lee, D.
Demarquay, G.
Ashina, S.
Yu, S.
Dabruzzo, B.
Guo, H.
Schwefel, B.
Trugman, J.
HEADACHE, 2023, 63 : 136 - 136
[23] Chronic migraine treatment with erenumab: Responder rates
Diener, Hans-Christoph
Brandes, Jan
Dolezil, David
Freeman, Marshall C.
McAllister, Peter J.
Winner, Paul
Cheng, Sunfa
Leonardi, Dean K.
Lenz, Robert A.
Mikol, Daniel D.
JOURNAL OF HEADACHE AND PAIN, 2017, 18
[24] Chronic Migraine Treatment with Erenumab: Responder Rates
Brandes, Jan L.
Diener, Hans-Christoph
Dolezil, David
Freeman, Marshall C.
Mcallister, Peter J.
Winner, Paul
Cheng, Sunfa
Leonardi, Dean
Lenz, Robert A.
Mikol, Daniel D.
CEPHALALGIA, 2017, 37 : 36 - 37
[25] Chronic Migraine Treatment with Erenumab: Responder Rates
Brandes, J. L.
Diener, H.
Dolezil, D.
Freeman, M. C.
McAllister, P. J.
Winner, P.
Cheng, S.
Leonardi, D. K.
Lenz, R. A.
Mikol, D. D.
HEADACHE, 2017, 57 : 197 - 198
[26] Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo- controlled, phase 3 trial
Pozo-Rosich, Patricia
Ailani, Jessica
Ashina, Messoud
Goadsby, Peter J.
Lipton, Richard B.
Reuter, Uwe
Guo, Hua
Schwefel, Brittany
Lu, Kaifeng
Boinpally, Ramesh
Miceli, Rosa
Ferreira, Rosa De Abreu
Mccusker, Emily
Yu, Sung Yun
Severt, Lawrence
Finnegan, Michelle
Trugman, Joel M.
LANCET, 2023, 402 (10404): : 775 - 785
[27] Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial
Schwedt, Todd J.
Lipton, Richard B.
Ailani, Jessica
Silberstein, Stephen D.
Tassorelli, Cristina
Guo, Hua
Lu, Kaifeng
Dabruzzo, Brett
Miceli, Rosa
Severt, Lawrence
Finnegan, Michelle
Trugman, Joel M.
CEPHALALGIA, 2022, 42 (01) : 3 - 11
[28] High-responder rates of atogepant in refractory chronic migraine: A retrospective analysis
Baek, William
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 455
[29] Safety and tolerability of ubrogepant for the acute treatment of migraine in participants taking atogepant for the preventive treatment of episodic migraine: Results from the TANDEM study
Ailani, Jessica
Lipton, Richard B.
Blumenfeld, Andrew M.
Mechtler, Laszlo
Klein, Brad C.
He, Molly Yizeng
Smith, Jonathan H.
Trugman, Joel M.
Ferreira, Rosa de Abreu
Brand-Schieber, Elimor
HEADACHE, 2024,
[30] Early Improvements With Atogepant for the Preventive Treatment of Migraine: Results From 3 Randomized Phase 3 Trials
Lipton, Richard B.
Gandhi, Pranav
Tassorelli, Cristina
Reuter, Uwe
Harriott, Andrea M.
Holle-Lee, Dagny
Gottschalk, Christopher H.
Neel, Brian
Liu, Yingyi
Guo, Hua
Stokes, Jonathan
Nagy, Krisztian
Dabruzzo, Brett
Smith, Jonathan H.
NEUROLOGY, 2025, 104 (02)

← 1 2 3 4 5 →